Future Opportunites Lies in Angola Pharmaceuticals Industry | Goldstein Market Intelligence

AUGUST 2020

FUTURE OPPORTUNITIES IN ANGOLA PHARMACEUTICALS Goldstein Market Intelligence

WRITTEN BY: Dennis Abraham Vice President Goldstein Market Intelligence

INTRODUCTION Angola is one of the biggest & emerging economies in Africa. Like other African countries oil crisis had a major impact even in Angola’s economy but it also led to new opportunities in pharmaceutical sector with the widening & diversifying the economy.

Angola’s pharmaceutical market is though expanding but still major demand is fulfilled by the imports. Also the country still lacks the supply of crucial medicines & treatment.

Only 37% of the essential drugs are in supply in public facilities. Moreover, the situation gets worse with the presence of few problems in Angola pharmaceutical market i.e. first the difficulty in enforcing the trademarks, second the struggle against the confusing drug names and last but not the least the issue of parallel imports.

But still the market players are grabbing their opportunities to enter the Angola pharmaceutical market.

©GOLDSTEIN MARKET INTELLIGENCE

PAGE 02

ANGOLA PHARMACEUTICALS DEMAND AT A GLANCE Angola’s pharmaceutical demand met majorly through the imports. The penetration of private players & private healthcare are coming across huge opportunities in Angola. But also the Angola government is taking initiative in the pharmaceutical industry to expand its capacity in the production of drugs & its effective supply in the country and thus reducing their dependency of drugs on imports.

Furthermore, the private sector is witnessed to be playing highly important role in health financing in Angola. Private healthcare will continue to expand to meet the quality healthcare. In present scenario the middle & upper class population tends to rely on healthcare & medical supplies from outside Angola.

250 200

Angola Healthcare Expenditure (USD) & Sources of Expenditure Outlook, 20152040

150 100 50 0

2015

2040

ŠGOLDSTEIN MARKET INTELLIGENCE

PAGE 03

Cardiology: Nearly 10% of the population suffers from cardiovascular diseases. Angola currently has limited pharmaceutical supply for the cardiology diseases but it is anticipated to have glowing future as there are rising opportunities for sales of cardiology devices and equipment on the back of improved diagnosis and treatment capacity of Angola.

Oncology: The Angolan Institute for Cancer Control (IACC) was established in 2014 to boost oncology care in the public sector, along with the effective policy implementation, programs and prevention plans.

HIV/AIDS: Angola HIV/AIDS prevalence rate is 2.4%. This rate is worrying for the government despite using multiple efforts to bring it down. Still the government is launching few programs like “testing & treating” for the people suffering from HIV/AIDS. Thus such serious developments are giving opportunities to big players for the supply of HIV/AIDS treatment drugs.

ANGOLA PHARMACEUTICALS SUPPLY VIEWPOINT The key health concerns in Angola are disease including malaria, typhoid, infectious & parasitic diseases, tuberculosis, respiratory and diarrheal diseases, sickle cell anemia, rabies, measles, cholera, and chronic non-communicable diseases.

©GOLDSTEIN MARKET INTELLIGENCE

PAGE 04

In 2016 Angola imported pharmaceuticals of around USD 270 million worth, majorly from India, China, and Portugal. The imports include both raw materials and finished products. India & China are the leading exporters of raw materials to Nigeria, accounting for 95% of total raw material imports.

Moreover the supply of pharmaceuticals in Angola varies from location to location. In the smaller pharmacies in the outskirts of major cities tends to sell unregulated & lower cost pharmaceuticals, which are often imported from India and China.

Whereas the urban facilities supply high quality & registered drugs. On the other hand, the private pharmacies sells branded pharmaceuticals, whereas the public hospital pharmacies sells the generic pharmaceuticals.

2012 2013 2014 2015 2016 2017 0

100

200

300

400

Angola Pharmaceutical Imports (USD Million), 2012-2018

ŠGOLDSTEIN MARKET INTELLIGENCE

PAGE 06

There is presence of nearly 220 importers and distributors of pharmaceuticals and medical devices across Angola. The local manufacturing is majorly limited to Nova Angomédica, a joint venture between the Angolan Ministry of Health and private company Suninvest. The Nova Angomédica manufacturers analgesic, antimalarial, anti-anemic, anti-tuberculosis, antiinflammatories, anti-allergic (pills and syrup forms), and also the saline solution and ointments.

Scan the QR code or click the link below for our study on Agola Pharmaceuticals Industry. https://www.goldsteinresearch.com

©GOLDSTEIN MARKET INTELLIGENCE

PAGE 08

About the author

Dennis Abraham Ph.D, senior vice president at Goldstein Market Intelligence (GMI), leads GMI's syndicated health and wellness resaerch. Before joining GMI, Dennis held a variety of senior leadership positions in global and regional consulting roles covering consumer and retail insights across a broad range of healthcare categories. Dennis has been providing cross-category strategic insights to healthcare brands for over 12 years on topics including digital disruption, ecommerce, and healthcare technology. Dennis holds a Ph.d from Brown University.

About Goldstein Market Intelligence

Goldstein Market Intelligence helping businesses to be successful at strategy and take informed decisions to grow the business in future. Goldstein Market Intelligence is one of the leading professional services firms, providing Intelligence Services, Consulting & Advisory and research related services to clients. We, at GMI practice works side by side with chief executives and their teams to create effective strategies and secure alignment across the organisation. ŠGOLDSTEIN MARKET INTELLIGENCE

PAGE 09